Part I

THE NATURE OF WORRY
Chapter 1

THE EPIDEMIOLOGY OF WORRY AND GENERALIZED ANXIETY DISORDER

Robert M. Holaway, Thomas L. Rodebaugh and Richard G. Heimberg

THE EPIDEMIOLOGY OF WORRY AND GENERALIZED ANXIETY DISORDER

Once considered synonymous with the cognitive components of anxiety (Mathews, 1990; O’Neill, 1985), worry has emerged as a more specific construct that can not only be distinguished from a larger subset of cognitive aspects of anxiety, but also studied in its own right (Davey, 1993; Davey, Hampton, Farrell & Davidson, 1992; Zebb & Beck, 1998). One of the first attempts to define worry was provided by Borkovec, Robinson, Pruzinsky, and DePree (1983, p. 10):

Worry is a chain of thoughts and images, negatively affect-laden and relatively uncontrollable; it represents an attempt to engage in mental problem-solving on an issue whose outcome is uncertain but contains the possibility of one or more negative outcomes; consequently, worry relates closely to the fear process.

More recent formulations have extended this definition of worry, describing it as an anxious apprehension for future, negative events (Barlow, 2002) that involves “a predominance of negatively valenced verbal thought activity” and minimal levels of imagery (Borkovec, Ray & Stober, 1998, p. 562). These definitions have been largely derived from participants’ reports regarding what they do when they worry.

Research on the epidemiology of worry has largely evolved over the past 20 years. Much research appears to have been spurred by the adoption of worry as the essential feature of generalized anxiety disorder (GAD) in the revised, third edition of the Diagnostic and Statistical Manual of Mental

Disorders (DSM-III-R; American Psychiatric Association [APA], 1987). These studies have provided valuable data regarding the prevalence, content, and functions of worry and GAD. In this chapter, we review the existing research on the prevalence and phenomenology of worry (both normal and pathological) and GAD and available data on gender, age, ethnic, and cultural differences in the manifestation and occurrence of both phenomena.

The Phenomenology of Normal and Pathological Worry

Few empirical studies have actually examined the occurrence and phenomenology of worry independent of GAD (Tallis, Davey & Capuzzo, 1994). As a result, much of our empirical understanding regarding what actually occurs when people worry, what they most often worry about, and how frequently they worry has been derived from examinations of nonanxious control groups. As noted by Ruscio (2002), these studies may not provide an accurate representation of the frequency and manifestation of normal worry because participants in these groups have been selected based on low worry scores and an absence of anxiety. In much of the empirical literature, normal worry has been regarded as “mild, transient, generally limited in scope, and experienced by the majority of individuals” (Ruscio, 2002, p. 378). However, without adequate studies of worry in normal individuals (i.e., not simply low-anxiety individuals), it is difficult to determine how much the above perception is based on specific characteristics of the available samples.

Tallis and colleagues (1994) conducted one of the few direct examinations of the phenomenology of non-pathological worry. In a mixed sample of 128 university students and working adults (aged 18–59), 38% reported worrying at least once per day; 19.4% indicated they worried once every 2–3 days; and 15.3% reported they worried about once a month. It is unclear how frequently the remaining 27.3% experienced worry. Participants were also asked how long their worry episodes typically lasted. About 24% reported that their worries were fleeting or lasted less than 1 minute, and 38% endorsed a typical duration of 1–10 minutes. The remainder endorsed longer durations of their typical worry (18%, 10–60 minutes; 11%, 1–2 hours; 9%, two hours or more). In addition, participants reported that they most often worried during the late evening or early morning hours and that their worries frequently occurred in response to impending matters, such as upcoming events or interpersonal interactions (Tallis et al., 1994). Participants’ mean score on a measure of pathological worry fell in the moderate range and was significantly lower than scores typically associated with a diagnosis of GAD (see Fresco, Mennin, Heimberg & Turk,
2003; Molina & Borkovec, 1994). In terms of worry content, 17% of respondents reported they worried most often about their competence at work, followed by academic performance (11%), health issues (10%), financial circumstances (10%), and intimate relationships (9%). Finally, 83% of respondents reported that they believed worry helped them to find solutions to problems in their environment (Tallis et al., 1994). This finding is, to some extent, consistent with recent research by Szabó and Lovibond (2002), in which 48% of naturally occurring worry episodes primarily reflected a problem-solving process (i.e., using worry to generate solutions to problematic situations), whereas 17% were characterized as primarily involving the anticipation of negative outcomes. Further examination revealed that more severe levels of worry were associated with reduced problem-solving success, although the causal direction of this relationship is unclear.

Studies have consistently, and perhaps not surprisingly, found that people who experience pathological worry as a part of GAD rate their worry as more pervasive and less controllable than people without pathological worry. Craske, Rapee, Jackel and Barlow (1989) examined several dimensions of worry by comparing individuals with DSM-III-R GAD to a nonanxious control group consisting of friends of clients receiving treatment for anxiety. Both groups reported similar ratings of worry duration, worry aversiveness, attempts to resist worry, anxiety associated with resisting worry, and perceived likelihood of the occurrence of worrisome outcomes. However, individuals in the nonanxious control group reported that they worried, on average, 18.2% of the day during the past month compared to 60.7% reported by the GAD group. In addition, nonanxious individuals rated their worries as more controllable, reported greater success in resisting or reducing their worries, indicated that their worries were more often associated with a specific and discernable precipitant, and perceived their worries to be more realistic than those reported by individuals with GAD. Other studies have also found differences with respect to the pervasiveness of worry, as nonanxious controls have consistently reported fewer worrisome topics than individuals with GAD (Borkovec, Shadick & Hopkins, 1991; Dugas et al., 1998; Hoyer, Becker & Roth, 2001; Roemer, Molina & Borkovec, 1997).

Studies comparing the content of worry among individuals with GAD and nonanxious controls have typically reported on the frequency of specific worry domains: 1) work and school, 2) family and interpersonal relationships, 3) financial issues, 4) illness, health, and injury, and 5) miscellaneous topics (e.g., minor matters, punctuality, home repairs). Across several investigations, roughly one-third of participants’ worries, regardless of GAD status, have pertained to family and interpersonal issues (Borkovec et al., 1991; Craske et al., 1989; Roemer et al., 1997). Relationships thus seem to be
WORRY AND ITS PSYCHOLOGICAL DISORDERS

a common source of worry, a conclusion further bolstered by two studies finding that over 70% of people with GAD endorsed frequent worry about either family or relationships (Dugas et al., 1998; Sanderson & Barlow, 1990). Contrary to this conclusion, Craske and colleagues (1989) found health and injury to be the most frequently reported topic of worry among individuals with GAD (30.6% of reported worries). However, most studies report health and injury worries to be rather infrequent in both GAD (Borkovec et al., 1991; Dugas et al., 1998; Roemer et al., 1997; Sanderson & Barlow, 1990) and nonanxious control groups (Craske et al., 1989; Roemer et al., 1997).

The most consistent finding regarding differences in worry content between nonanxious controls and GAD samples has pertained to worry regarding miscellaneous topics, such as car troubles or being late for appointments. Across three studies, miscellaneous worry topics reported by nonanxious control groups comprised 0%–19.7% of all reported worries, whereas miscellaneous worries among individuals with GAD comprised between 25.2%–31.3% of reported worries (Borkovec et al., 1991; Craske et al., 1989; Roemer et al., 1997). Other content differences between individuals with and without GAD have been observed with regard to worry about work and school. Two studies found nonanxious controls to report a greater proportion of worries related to work and school (30.4%–36.6%) than individuals with GAD (13.9%–22%) (Craske et al., 1989; Roemer et al., 1997), although Borkovec and colleagues (1991) found the opposite. The conclusion that people in nonanxious control groups worry more about work and school is fairly consistent with Tallis and colleagues’ (1994) assessment of non-pathological worry, in which the most frequent topics of concern reported by participants pertained to academic performance and competence at work. Similar to concerns regarding work and school, worries about financial circumstances have generally been more frequently reported by individuals without GAD, as two studies have reported the proportion of total worries pertaining to finances to range from 12.5%–26.1% among nonanxious control groups and 2.8%–8.9% among GAD samples (Borkovec et al., 1991; Craske et al., 1989). However, in contrast, Roemer and colleagues (1997) found individuals with GAD to report a greater proportion of worries related to financial circumstances (10.8%) than nonanxious controls (5.6%).

The studies reviewed above have revealed several similarities and differences in the phenomenology of worry among individuals with and without GAD. Most notably, individuals with GAD spend significantly more time worrying, report more worry topics, and perceive themselves as having considerably less control over their worry than nonanxious controls. In addition, miscellaneous worry topics appear to be more prevalent among individuals with GAD than nonanxious controls. Most similarities
observed between the two groups have regarded the frequency of worries pertaining to family and interpersonal relationships, with roughly a third of all reported worries relating to this topic.

Despite these general patterns, there have been many inconsistencies across studies. Several factors may account for these differences. First, with the exception of Roemer et al. (1997), sample sizes for both GAD and nonanxious control groups have been relatively small (e.g., \( n = 13 - 31 \)), which may limit external validity. Second, the manner in which the frequency and content of worry was assessed varied by study. For example, whereas participants in the Craske et al. (1989) study monitored and recorded the nature of their worry each day for three weeks, other studies have assessed worry phenomenology using diagnostic interviews (e.g., Roemer et al., 1997). Finally, demographic differences across study samples, especially with respect to age, gender, and employment, may have influenced the frequency of specific worry topics, as these concerns seem likely to shift according to the nature of one’s daily life.

**Differentiating Pathological Worry from GAD**

Recent research by Ruscio, Borkovec, and Ruscio (2001) has provided empirical support for a dimensional structure of worry, suggesting that normal and pathological worry represent opposite ends of a continuum, not discrete constructs. However, in most cases, investigations of normal and pathological worry have typically examined individuals with a diagnosis of GAD and have rarely examined pathological worry independent of GAD, leaving pathological worry outside the context of GAD poorly understood (Ruscio, 2002; Ruscio & Borkovec, 2004).

In an attempt to identify delimiting characteristics of pathological worry and GAD, Ruscio (2002) recently compared high worriers with and without a diagnosis of GAD. Surprisingly, only 20% of individuals who reported experiencing extreme levels of pathological worry (worry scores above the threshold commonly associated with GAD) actually met diagnostic criteria for the disorder. Follow-up analyses indicated that, across two samples, 68%–78% of people who reported high levels of worry but not GAD met only 0–1 of the four required DSM-IV criteria, with chronic/excessive worry and associated distress and impairment best differentiating individuals with GAD from high worriers without GAD (Ruscio, 2002, Study 1). Individuals with GAD also reported greater levels of depression, more frequent worry, and less control over their worry. In a follow-up study, individuals with high levels of worry but without GAD experienced all symptoms of GAD less severely than individuals with GAD, even though
they reported their worry to be excessive and uncontrollable (Ruscio, 2002, Study 2).

Ruscio’s (2002) findings underscore the need for future studies to distinguish GAD from pathological worry. Specifically, they suggest that examining differences between worry in normal participants and participants with GAD may not actually provide information about the differences between nonpathological and pathological worry. In a recent comparison of people with high worry who either did or did not have GAD, Ruscio and Borkovec (2004) found that negative beliefs about worry (e.g., “worry is harmful”) were specific to participants with GAD. In line with Roemer and colleagues’ (1997) position that worry may function as a strategy for avoidance of more emotional topics among persons with GAD, Holaway, Hambrick and Heimberg (2003) found that people with GAD reported experiencing their emotions as more intense and more confusing than people without GAD who experienced high levels of worry. Such results, although preliminary, suggest that pathological worry within the context of GAD may be subject to additional factors (e.g., different beliefs about worry, increased emotion dysregulation) that may render it significantly different from pathological worry without GAD. This caveat should be kept in mind when large-scale epidemiological studies, which concern GAD rather than worry per se, are reviewed below.

The Epidemiology of Generalized Anxiety Disorder

Since their first iteration in DSM-III (APA, 1980) to their current version in DSM-IV (APA, 1994), the diagnostic criteria for GAD have been revised repeatedly, with revisions resulting in a greater focus on the presence of excessive and uncontrollable worry, an increase in the required duration of symptoms, fewer required physical symptoms, and the added requirement that worry and associated symptoms be accompanied by significant distress or impairment. In later editions, GAD was no longer considered a residual category that could only be diagnosed in the absence of other anxiety disorders. These significant changes to the structure of GAD have hampered long-term investigations of the course of the disorder and resulted in considerable heterogeneity in studies examining prevalence rates (Kessler, Walters & Wittchen, 2004; Wittchen, Zhao, Kessler & Eaton, 1994). Nevertheless, several epidemiological surveys provide valuable information regarding the prevalence, course, and associated features of GAD.

Prevalence

Table 1.1 shows the current, 12-month, and lifetime prevalence rates for GAD in population-based surveys of adults conducted in several countries.
Table 1.1  Prevalence of generalized anxiety disorder in the community

<table>
<thead>
<tr>
<th>Source</th>
<th>Country</th>
<th>Diagnostic Criteria</th>
<th>Assessment Instrument</th>
<th>Sample Size</th>
<th>Age of Participants</th>
<th>Current Prevalence</th>
<th>12-Month Prevalence</th>
<th>Lifetime Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blazer et al., 1991</td>
<td>United States</td>
<td>DSM-III</td>
<td>DIS</td>
<td>3,422</td>
<td>18–65+</td>
<td>1.2%</td>
<td>3.6%</td>
<td>6.6%</td>
</tr>
<tr>
<td></td>
<td>United States</td>
<td>DSM-III</td>
<td>DIS</td>
<td>2,432</td>
<td>18–65+</td>
<td>1.4%</td>
<td>2.0%</td>
<td>4.1%</td>
</tr>
<tr>
<td></td>
<td>United States</td>
<td>DSM-III</td>
<td>DIS</td>
<td>2,683</td>
<td>18–65+</td>
<td>1.3%</td>
<td>2.9%</td>
<td>6.6%</td>
</tr>
<tr>
<td>Chen et al., 1993</td>
<td>China</td>
<td>DSM-III</td>
<td>DIS</td>
<td>7,229</td>
<td>18–64</td>
<td>—</td>
<td>—</td>
<td>7.8% males/11.1% females</td>
</tr>
<tr>
<td>Hwu et al., 1989</td>
<td>Taiwan</td>
<td>DSM-III</td>
<td>DIS</td>
<td>5,005</td>
<td>18–64</td>
<td>0.8%</td>
<td>1.2%</td>
<td>3.7%</td>
</tr>
<tr>
<td>Bijl et al., 1998</td>
<td>Netherlands</td>
<td>DSM-III-R</td>
<td>CIDI</td>
<td>7,076</td>
<td>18–64</td>
<td>2.0%</td>
<td>—</td>
<td>2.3%</td>
</tr>
<tr>
<td>Faravelli et al., 1989</td>
<td>Italy</td>
<td>DSM-III-R</td>
<td>SADS-L</td>
<td>1,110</td>
<td>15–61+</td>
<td>—</td>
<td>—</td>
<td>3.9%</td>
</tr>
<tr>
<td>Kawakami et al., 2004</td>
<td>Japan</td>
<td>DSM-III-R</td>
<td>CIDI</td>
<td>1,029</td>
<td>20–65+</td>
<td>0.8%</td>
<td>—</td>
<td>1.4%</td>
</tr>
<tr>
<td>Offord et al., 1996</td>
<td>Canada</td>
<td>DSM-III-R</td>
<td>CIDI</td>
<td>8,116</td>
<td>15–64</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Wang et al., 2000</td>
<td>United States</td>
<td>DSM-III-R</td>
<td>CIDI-SF</td>
<td>3,032</td>
<td>25–74</td>
<td>—</td>
<td>—</td>
<td>3.3%</td>
</tr>
<tr>
<td>Wittchen et al., 1994</td>
<td>United States</td>
<td>DSM-III-R</td>
<td>CIDI</td>
<td>8,098</td>
<td>15–54</td>
<td>1.6%</td>
<td>3.1%</td>
<td>5.1%</td>
</tr>
<tr>
<td>Jenkins et al., 1997</td>
<td>Great Britain</td>
<td>ICD-10</td>
<td>CIS-R</td>
<td>10,108</td>
<td>16–64</td>
<td>3.1%</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bhagwanjee et al., 1998</td>
<td>South Africa</td>
<td>DSM-IV</td>
<td>Clinical Interview</td>
<td>354</td>
<td>18–50+</td>
<td>3.7%</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Carter et al., 2001</td>
<td>Germany</td>
<td>DSM-IV</td>
<td>CIDI</td>
<td>4,181</td>
<td>18–65</td>
<td>—</td>
<td>1.5%</td>
<td>—</td>
</tr>
<tr>
<td>Hunt et al., 2002</td>
<td>Australia</td>
<td>DSM-IV</td>
<td>CIDI</td>
<td>10,641</td>
<td>18–65+</td>
<td>2.8%</td>
<td>3.6%</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICD-10</td>
<td></td>
<td></td>
<td></td>
<td>3.6%</td>
<td>5.1%</td>
<td></td>
</tr>
</tbody>
</table>

Note: ECA = Epidemiologic Catchment Area Study; DIS = Diagnostic Interview Schedule; CIDI = Composite International Diagnostic Interview; CIDI-SF = Composite International Diagnostic Interview—Short Form; SADS-L = Schedule for Affective Disorders and Schizophrenia—Lifetime Version; CIS-R = Revised Clinical Interview Schedule.
around the world. Most likely because the diagnostic criteria for GAD in DSM-III-R are more stringent than the criteria in DSM-III, prevalence rates appear to have dropped from studies employing DSM-III to those using DSM-III-R. Though lifetime prevalence rates of DSM-IV GAD among adults in the general population have yet to be reported, existing studies have found the current and 12-month prevalence rates for the disorder to be equivalent to, or perhaps slightly higher than the rates found using the DSM-III-R.

Fewer prevalence data for GAD are available from epidemiological surveys using the International Classification of Diseases and Related Health Problems, 10th revision (ICD-10; World Health Organization, 1990). Surveys employing ICD-10 criteria have generally found current and 12-month prevalence rates of GAD to be relatively comparable to those for DSM-III-R and DSM-IV (Hunt et al., 2002; Wittchen et al., 1994) (see Table 1.1). However, larger differences have been observed in lifetime prevalence rates, which have been attributed to the less stringent criteria of ICD-10 (Wittchen et al., 1994). Interestingly, Slade and Andrews (2001) reported that, though ICD-10 and DSM-IV yield similar 12-month prevalence rates for GAD (3.0% and 2.6%, respectively), less than 50% of those diagnosed by one system were also diagnosed by the other, suggesting that the two systems diagnose overlapping, but largely different, groups of people.

The prevalence of GAD has also been assessed in primary care settings. Findings from large scale investigations in several countries indicate that GAD is one of the most frequently diagnosed mental disorders in primary care, with a current prevalence rate between 3.7% and 8% (Maier et al., 2000; Olsson et al., 1997; Ormel et al., 1994; Üstün & Sartorius, 1995) and a 12-month prevalence rate of 10.3% (Ansseau et al., 2004). Among high utilizers of medical care, 21.8% of those who reported significant emotional distress met criteria for a current diagnosis of GAD, whereas 40.3% met criteria for GAD at some point in their lives (Katon et al., 1990). As noted by Wittchen (2002), the higher prevalence of GAD in primary care settings compared to the general population differs from patterns observed in most other anxiety disorders, suggesting that individuals with GAD are likely to be frequent utilizers of health care services.

### Age of Onset and Clinical Course

Few population-based surveys have reported the average age of onset of GAD. Based on findings of the Epidemiologic Catchment Area (ECA) study, Blazer and colleagues (1991) reported that age of onset for individuals with GAD was distributed rather evenly across the lifespan. However, investigations of clinical populations have found the typical age of
onset of GAD to occur between the late teens and late 20s, with later onset occurring when GAD develops after another anxiety disorder (Barlow, Blanchard, Vermilyea, Vermilyea & DiNardo, 1986; Brawman-Mintzer et al., 1993; Hoehn-Saric, Hazlett & McLeod 1993; Massion, Warshaw & Keller, 1993; Woodman, Noyes, Black, Schlosser & Yagla, 1999; Yonkers, Massion, Warsaw & Keller, 1996).

Epidemiological surveys and long-term investigations of clinical course have often found GAD to be chronic and unremitting. In the ECA study, 40% of respondents with GAD reported a duration of longer than five years (Blazer et al., 1991), and participants in clinical samples have often reported a duration of more than 20 (Barlow et al., 1986; Woodman et al., 1999; Yonkers et al., 1996). Yonkers and colleagues (1996) found only 40% of individuals with GAD had a full remission of symptoms after two years; the same study later showed a partial remission rate of less than 50% and a full remission rate of 38% after five years (Yonkers, Dyck, Warshaw & Keller, 2000). Among individuals who achieved partial or full remission, 39% and 27% were found to have a full relapse during the five-year follow-up period. Similarly, in a study by Woodman and colleagues (1999), 45% of individuals with GAD were found to reach full remission during a five-year follow-up period; however, only 18% of the sample was in full remission at the five-year assessment point, indicating significant relapse. Factors most predictive of chronicity and relapse in GAD over the long-term have been found to be early age of onset and the presence of comorbid diagnoses, particularly Axis II disorders (Mancuso, Townsend & Mercante, 1993; Massion et al., 2002; Woodman et al., 1999; Yonkers et al., 2000).

Comorbidity and Associated Impairment

Early findings from the ECA study indicated a lifetime diagnosis of DSM-III GAD was associated with at least one additional Axis I disorder in 58% to 65% of respondents, with panic disorder and major depression the most frequent comorbid diagnoses (Blazer et al., 1991). As noted by Kessler and colleagues (2004), high rates of comorbidity for DSM-III GAD observed in early studies resulted in significant modifications to the disorder’s diagnostic criteria, particularly the increase in required duration.

Despite these changes, high rates of comorbidity continue to be found. In the National Comorbidity Study (NCS), 66.3% of respondents currently meeting criteria for DSM-III-R GAD and 90.4% of individuals with a lifetime diagnosis were found to meet criteria for at least one additional Axis I diagnosis, with major depression being the most frequent co-occurring disorder (Wittchen et al., 1994). Findings from epidemiological surveys of the 12-month prevalence of DSM-IV GAD show 93.1% of respondents in
one study meeting criteria for an additional Axis I disorder (Carter et al., 2001) and 60.6% of respondents in a separate study meeting criteria for an Axis II disorder (Grant et al., 2005). Though GAD appears to be a highly comorbid disorder in general population studies, Wittchen and colleagues (1994) showed that the frequency of individuals with GAD reporting one or more comorbid diagnoses is not much higher than rates observed in other anxiety or mood disorders.

In clinical studies of individuals with GAD, rates of comorbid Axis I disorders have ranged from 45% to 98% (Barlow et al., 1986; Brawman-Mintzer et al., 1993; DiNardo & Barlow, 1990; Goisman, Goldenberg, Vasile & Keller, 1995; Sanderson, DiNardo, Rapee & Barlow, 1990; Yonkers et al., 1996). Similar to findings in the general population, major depressive disorder has frequently been the most commonly diagnosed comorbid disorder among individuals with GAD, followed by social phobia, specific phobia, and panic disorder (e.g., Brawman-Mintzer et al., 1993; Goisman et al., 1995; Massion et al., 1993). Recent research also found personality disorders to be fairly common among individuals with GAD. For example, 37.7% of individuals with GAD participating in the Harvard/Brown Anxiety Research Program study met criteria for one or more Axis II disorders, with avoidant personality disorder being the most frequent (Dyck et al., 2001).

In addition to high rates of comorbidity, GAD has also been found to be associated with significant impairment in social and occupational functioning (Kessler, DuPont, Berglund & Wittchen, 1999; Maier et al., 2000), as well as reduced quality of life (Massion et al., 1993). In a sample of primary care patients, Olfson and colleagues (1997) found individuals with GAD to report greater disability and more absences from work than individuals without a mental disorder. Similarly, Ormel and colleagues (1994) found individuals with pure GAD to report significantly greater occupational impairment and work absences than individuals without a mental disorder, even after controlling for the presence of co-occurring medical illnesses.

**Ethnic and Cross-Cultural Differences**

Based on findings from available epidemiological surveys, most countries around the world appear to have a fairly similar prevalence of GAD (see Table 1.1). Genuine cross-cultural differences are difficult to determine given differences in methodology, particularly in diagnostic and assessment methods. However, an examination of ICD-10 GAD across several primary care centers revealed significant differences in prevalence rates between countries, with current GAD prevalence rates highest in Rio de Janeiro, Brazil (22.6%) and lowest in Ankara, Turkey (1.0%; Maier et al., 2000).
Though several studies have examined differences in the occurrence of anxiety among various ethnic groups within a specific country, few have reported specifically on differences in the prevalence of GAD (e.g., Jenkins et al., 1997). Overall, findings from three epidemiological surveys conducted in the US have revealed few differences in the prevalence of GAD among representative ethnic groups (Blazer et al., 1991; Wang et al., 2000; Wittchen et al., 1994).

In an examination of ethnic differences in worry in a nonclinical population, Scott, Eng, and Heimberg (2002) compared Caucasian, African-American, and Asian/Asian-American students on measures of pathological worry, worry domains, and generalized anxiety. No differences were observed among the three groups with respect to pathological worry or generalized anxiety; however, African-American participants reported significantly less worry regarding relationship stability, self-confidence, future aims, and work incompetence than the other two groups. In addition, Asian/Asian-American participants endorsed significantly more worry regarding future goals than the other groups. Further, whereas Caucasian and Asian/Asian-American students reported a similar amount of worry across domains, African-American participants reported worrying most frequently about financial issues (Scott et al., 2002).

Gender and Lifespan Differences

Several studies have found GAD to be roughly twice as prevalent among women as men (e.g., Bijl et al., 1998; Blazer et al., 1991; Carter et al., 2001; Hunt et al., 1997; Wittchen et al., 1994). However, though Maier and colleagues (2000) found GAD to be more prevalent among female primary care patients in most countries, there were contrary findings in some locations (e.g., Nagasaki, Japan).

The few studies of gender differences in worry have found women to worry more than men (e.g., Lewinsohn, Gotlib, Lewinsohn, Seeley & Allen, 1998; Stavosky & Borkovec, 1988). Robichaud, Dugas and Conway (2003) found women to score higher than men on two widely-used worry measures. Few differences in worry content were observed; however, women were found to worry significantly more about self-confidence than men.

Available data on the community prevalence of GAD across the lifespan are shown in Table 1.2. Based on these findings, GAD appears to be most prevalent between the ages of 25 and 54, with lower rates of occurrence above and below that range. However, investigations of GAD among individuals younger than 18 (overanxious disorder [OAD] in DSM-III and DSM-III-R) and older than 65, have also found the disorder to be fairly prevalent. For
Table 1.2  Twelve-month prevalence of generalized anxiety disorder by age

<table>
<thead>
<tr>
<th>Source</th>
<th>Country</th>
<th>Diagnostic Criteria</th>
<th>18–24</th>
<th>25–34</th>
<th>35–44</th>
<th>45–54</th>
<th>55–64</th>
<th>65+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang et al., 2000</td>
<td>United States</td>
<td>DSM-III-R</td>
<td>—</td>
<td>3.2%</td>
<td>5.0%</td>
<td>3.8%</td>
<td>1.4%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Wittchen et al., 1994</td>
<td>United States</td>
<td>DSM-III-R</td>
<td>1.4%</td>
<td>4.1%</td>
<td>3.4%</td>
<td>3.5%</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Carter et al., 2001</td>
<td>Germany</td>
<td>DSM-IV</td>
<td>1.0%</td>
<td>0.7%</td>
<td>1.5%</td>
<td>2.0%</td>
<td>2.2%</td>
<td>—</td>
</tr>
<tr>
<td>Hunt et al., 2002</td>
<td>Australia</td>
<td>DSM-IV</td>
<td>3.0%</td>
<td>3.9%</td>
<td>4.5%</td>
<td>4.9%</td>
<td>3.0%</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

Note: *15–24 age range; *≥45 age range; *≥55 age range.
example, the prevalence rate of OAD in children ages 7–11 at a primary care center was 4.6% (Costello et al., 1988), whereas the occurrence of OAD in a sample of 11 year-old children was 2.9% (Anderson, Williams, McGee & Silva, 1987).

Several studies have found GAD to be the most prevalent anxiety disorder among elderly individuals (e.g., Beekman et al., 1998; Flint, 1994). As shown in Table 1.2, the 12-month prevalence of GAD in people 65 years of age and older appears to fall between 0.8% and 1.6%. However, a recent epidemiological survey of 4,051 individuals between the ages of 65 and 86 yielded higher rates, with 3.2% of participants meeting criteria for current GAD (Schovers, Beekman, Deeg, Jonker & van Tilburg, 2003).

Conclusion

Normal worry appears to be a fairly common phenomenon, and recent research suggests that pathological worry independent of GAD may be more prevalent that previously thought. Though some similarities have emerged between normal worry and worry associated with GAD, most investigations have found that individuals with GAD worry more frequently, worry more about miscellaneous topics, and find their worry more difficult to control than their nonanxious counterparts. However, as noted by Ruscio (2002), most comparisons of normal and pathological worry to date have involved individuals with GAD and those not meeting criteria for an anxiety disorder. Thus, given that most individuals who report pathological worry do not actually meet criteria for GAD, observed differences between GAD and nonanxious control samples may not be representative of true differences between normal and pathological worry. Future research would greatly benefit from more focused examinations of what actually constitutes normal worry, as well as examinations of differences in properly operationalized normal and pathological worry.

Since becoming an official diagnostic category in 1980, GAD has been a frequent topic of study, and valuable information regarding its prevalence, course, and associated characteristics have accrued. Epidemiological surveys and clinical investigations conducted around the world suggest that GAD is a highly prevalent disorder in both the general population and primary care settings and typically has a chronic and unremitting course. In addition, GAD is commonly associated with high rates of comorbidity and impairment, and revisions to the diagnostic criteria have had only a modest effect on prevalence and comorbidity rates. However, in contrast to what has commonly been argued, Wittchen and colleagues (1994) have shown GAD to have comorbidity rates not much higher than that associated with other anxiety and mood disorders.
Though GAD appears to be equally prevalent across the lifespan, most investigations have found a gender ratio of 2:1, with the disorder being more common in women. Interestingly, though this same pattern has been observed in several countries around the world, a few cultures have reported contrary findings. Further investigation of cross-cultural differences, especially in non-industrialized countries, would be of value. Ethnic differences in the prevalence of GAD have been less commonly reported, although most investigations conducted in the United States have revealed few differences. It is important to note, however, that attempts to assess differences across ethnic groups within a specific country have often been hampered by small sample sizes. Focused investigations of the prevalence, phenomenology, and course of GAD across a wide range of cultures and ethnic groups is an important research agenda.

REFERENCES


18 WORRY AND ITS PSYCHOLOGICAL DISORDERS


THE EPIDEMIOLOGY OF WORRY AND GENERALIZED ANXIETY DISORDER


20 WORRY AND ITS PSYCHOLOGICAL DISORDERS


